Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Wall Street analysts say Johnson & Johnson's decision to spin off its consumer division is overall a smart business move but it could come with some risks.

Johnson & Johnson is spinning off its consumer division, which could come with risks

The announced shakeup is the biggest in the company's 135-year history.

Johnson & Johnson To Spin Off Its Consumer Division and Focus On Pharmaceuticals

Johnson & Johnson said new study results provide “real world evidence” that its COVID-19 vaccine “demonstrates durable protection against breakthrough Infection, hospitalization, and intensive care unit admission in the United States.”

Dow Jones Newswires: J&J: Study shows ‘real world evidence' of COVID vaccine's protection against breakthrough infection

NEW BRUNSWICK, N.J., Jan. 6, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson & Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions.

Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States

Archer-Daniels-Midland Company

Alarm.com

Chevron

DuPont de Nemours

Squarespace

Xylem

As we turn the page on the calendar to 2022, here are some of the more dependable ideas -- and a few risky ones -- for stocks to buy. The post 7 Best Stocks to Buy to Kick Off the New Year appeared first on InvestorPlace.

7 Best Stocks to Buy to Kick Off the New Year

AbbVie

Biogen

Bristol-Myers

Hoth Therapeutics

Longeveron

Pfizer

The Alzheimer's Disease treatment market is known for its vast potential given the fact that there are hardly any active drugs and therapies that produce any real improvements in patients' conditions.

These Emerging Biotechs Could Beat Alzheimer's Disease

This battle-tested method to beat both the market and inflation will never go out of style.

1 Simple Strategy to Beat Inflation in 2022

Nevada has agreed to join a proposed nationwide settlement worth up to $26 billion resolving claims that three large U.S. drug distributors and the drugmaker Johnson & Johnson fueled a deadly opioid epidemic, the state's attorney general said on Tuesday.

Nevada to join $26 billion opioid settlement with J&J, drug distributors

Genuine Parts

Lowe's

Altria

Target

Sturdy businesses and reliable dividend growth? Yes, please.

5 Top Dividend Kings to Buy in 2022 and Hold Forever

NEW BRUNSWICK, N.J., Jan. 4, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2022 of $1.06 per share on the company's common stock.

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2022

The world's largest healthcare company is moving to develop a broad and underappreciated drug portfolio and spin off its consumer business.

Johnson & Johnson, Shaking Off Its Stodgy Image, Is One of Our Stock Picks for 2022

Johnson & Johnson's (JNJ) COVID booster vaccine demonstrates 85% effectiveness against COVID-related hospitalization in South Africa, with Omicron becoming the dominant variant.

J&J (JNJ) COVID Booster Jab Shows Effectiveness Against Omicron

The stock price of Johnson & Johnson (NYSE: JNJ) increased by 0.44% in the most recent trading session. This is why it happened.

Johnson & Johnson Stock (JNJ): Why The Price Increased

Amgen

BlackRock Taxable Municipal Bond Trust

BlackRock Science & Technology

Calamos Convertible Opportunities And Income Fund

Clorox

Digital Realty Trust

DNP Select Income Fund Inc

Enbridge

Enterprise Products Partners

Fastenal

Flaherty & Crumrine Preferred Securities Income Fund Inc

Home Depot

Kimberly-Clark

Lockheed Martin

McDonald's

NextEra Energy

Annaly Capital

PIMCO Dynamic Income Fund

Invesco QQQ

Cohen & Steers Quality Income Realty Fund

iShares 20+ Year Treasury Bond ETF

Texas Instruments

No portfolio or strategy can be perfect. But can there be a strategy that can work well in a bull market, a bear market, or a stagnant market, generate a decent income, and conserve capital, all at the same time? We also want our strategy to avoid roller-coaster rides of index investing, have low volatility and limited drawdowns in case of deep corrections.

The Near-Perfect Portfolio For The Bull Markets And The Bear Markets

J&J (JNJ) submits a Biologics License Application, seeking approval for its bispecific antibody candidate teclistamab as a treatment option for the heavily pretreated multiple myeloma patients.

J&J (JNJ) Seeks FDA Approval for Myeloma Drug Teclistamab

An additional dose of the one-shot J&J vaccine boosted the odds of avoiding hospitalization to 85%, according to a new study from South Africa.

Johnson & Johnson COVID booster offers serious protection against hospitalization from omicron variant

Johnson & Johnson (NYSE:JNJ) stock is up 0.5% to trade at $172.38 at last check, after the blue-chip pharma giant provided an update for its Covid-19 booster shot.

Call Traders Blitz Blue-Chip Vaccine Maker After Update

A booster dose of Johnson & Johnson's Covid-19 vaccine was up to 85% effective at preventing hospitalizations caused by the Omicron variant in South Africa, according to a study.

J&J Booster Cuts Hospitalizations Linked to Omicron: Study

Johnson & Johnson said Thursday that a South African Phase 3 study showed that its a booster shot of its COVID-19 vaccine was 85% effective in preventing COVID-19-related hospitalization. The drug maker said the study, conducted by the South African Medical Research Council, was conducted from mid-November to mid-December, which is after omicron became the dominant variant.

J&J's COVID-19 vaccine booster was 85% effective against hospitalization, in South Africa study

NEW BRUNSWICK, N.J., Dec. 30, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced new preliminary results from the South African Phase 3b Sisonke study which showed that a homologous (same vaccine) booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S) demonstrated 85 percent effectiveness against COVID-19-related hospitalization.

News for Johnson & Johnson Stock (JNJ)